AI Article Synopsis
- The study aimed to compare the time to next treatment for patients with chronic lymphocytic leukemia who started first-line treatment with either ibrutinib or acalabrutinib.
- Data from US specialty pharmacies covering records from November 21, 2018, to April 30, 2022, were analyzed, focusing on patients who began treatment after acalabrutinib's approval.
- Results indicated that 5.9% of patients on ibrutinib and 7.5% of those on acalabrutinib initiated next treatment, with acalabrutinib patients being 89% more likely to start next treatment sooner, suggesting it may be more effective in the real world.
Article Abstract
To investigate real-world time to next treatment in patients with chronic lymphocytic leukemia initiating first-line (1L) ibrutinib or acalabrutinib. US specialty pharmacy electronic medical records (21/11/2018-30/4/2022) were used; patients initiated 1L on/after 21/11/2019 (acalabrutinib approval). Among 710 patients receiving ibrutinib, 5.9% initiated next treatment (mean time to initiation = 9.2 months); among 373 patients receiving acalabrutinib, 7.5% initiated next treatment (mean time to initiation = 5.9 months). Adjusting for baseline characteristics, acalabrutinib-treated patients were 89% more likely to initiate next treatment (hazard ratio = 1.89; p = 0.016). This study addresses a need for real-world comparative effectiveness between 1L ibrutinib and acalabrutinib and shows that next treatment (a clinically meaningful measure for real-world progression) occurred less frequently with 1L ibrutinib.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fon-2023-0436 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!